Search companies

Live

IMAGION BIOSYSTEMS LIMITED (ASX: IBX)

Health care · News and insights

IBX: $0.006 +50.00% · MC: $4M

Latest IBX announcements

Imagion Signs First US Site Agreement for HER2 Breast Cancer Trial

2026-11-17 · Health care

IBX: $0.006 +50.00% · MC: $4M

Imagion Biosystems has signed its first US clinical trial site agreement for its MagSense HER2+ breast cancer imaging agent, with patient recruitment anticipated to begin shortly after site activation. Site-startup activities are underway at seven selected sites, and the trial is registered on ClinicalTrials.gov; the company expects the study to take 18–24 months.

Updated 2026-11-17 09:00
Share
SourcesIBX First Site Agreement Advances Phase 2 Trial Plans
Comments

Imagion Biosystems Director Resigns as Joint Company Secretaries Are Appointed

2026-10-30 · Health care

IBX: $0.005 +0.00% · MC: $4M

Melanie Leydin will resign as a non-executive director and company secretary, effective today, as she retires and focuses on other commitments. Mariia Skorikova and Tony Di Pietro will replace her as joint company secretaries, while the board reviews its composition and may consider adding an independent director.

Updated 2026-10-30 14:26
Share
SourcesIBX Announces NED Resignation & Change of Company Secretary
Comments